Impact of Intensive LDL Cholesterol Lowering on Coronary Artery Atherosclerosis Progression: A Serial CT Angiography Study

• Published in: JACC. Cardiovascular imaging 2017-04, Vol.10 (4), p.437-446
• Main Authors: Shin, Sanghoon, Park, Hyung-Bok, Chang, Hyuk-Jae, Arsanjani, Reza, Min, James K, Kim, Yong-Jin, Lee, Byoung Kwon, Choi, Jung-Hyun, Hong, Geu-Ru, Chung, Namsik
• Format: Article
• Language: English
• Subjects: Aged; Biomarkers - blood; Cholesterol, LDL - blood; Computed Tomography Angiography; Coronary Angiography - methods; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - etiology; Coronary Vessels - diagnostic imaging; Disease Progression; Down-Regulation; Dyslipidemias - blood; Dyslipidemias - complications; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome
• ISSN: 1876-7591
• DOI: 10.1016/j.jcmg.2016.04.013

The aim of this study was to explore the relationship between temporal changes in coronary plaque volume and the intensity of lipid-lowering treatments, utilizing coronary computed tomography angiography (CTA). Coronary CTA has acceptable accuracy in terms of quantitative measurement of plaque volume. Although, coronary CTA is perhaps capable of identifying the differences in plaque volume progression according to the intensity of lipid lowering treatment, to date, few studies have examined this notion. In this multicenter, observational study, the authors reviewed 467 patients who underwent serial coronary CTA with a scan period of more than 2 years (median 3.2 years [2.4 to 4.8]) apart, and whose laboratory data were available within 1 month of both the baseline and follow-up coronary CTA. Among them, 147 patients (comprising 336 vessels) with visible plaque were enrolled in this study. The authors performed quantitative assessment of coronary plaque in both. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) with a cut off value below 70 mg/dl at follow-up were compared with those who did not. Patients with LDL-C below 70 mg/dl displayed a significant attenuation in plaque progression as compared with those with follow-up LDL-C levels ≥70 mg/dl (12.7 ± 38.2 mm vs. 44.2 ± 73.6 mm , respectively; p = 0.014). In multivariate analysis, factors influencing plaque progression per year was follow-up LDL-C levels ≥70 mg/dl (beta 0.193; p = 0.021). Strict LDL-C control appeared to significantly attenuate plaque volume progression based on noninvasive quantitative assessment by coronary CTA.